Bone-related problems represent the principal unmet medical need in Gaucher disease (GD). 75% of GD type 1 patients develop skeletal complications, including bone remodeling defects, osteopenia, osteoporosis, marrow infiltration, avascular necrosis, and osteolysis. However, the underlying cellular/molecular basis of bone involvement and related complications in GD are not fully known. Neither are there any bone-specific markers associated with individual bone pathology. Early diagnosis of bone disease is the key issue for planning individual therapy to prevent and reverse bone disease in GD.
This clinical observational study is designed to identify specific biomarkers for bone involvement in patients with GD1 with decreased bone density and/or bone structural abnormalities Aims: 1. Identify novel immune cell surface and biochemical markers in peripheral blood correlating with bone involvement in GD. 2. Assess the correlation between cytokine levels in peripheral blood and the severity of bone involvement in GD. 3. Assess the relationship between glycosphingolipids accumulation and macrophage activation with specific bone markers and GD severity.
Study Type
OBSERVATIONAL
Enrollment
40
LDRTC
Fairfax, Virginia, United States
RECRUITINGMeasure biomarkers level in molar/l/h
Bone homeostasis is dependent on the balance of deposition by osteoblasts DMP-1, OSCAR, Calcitonin, Lyso-GB1, chitotriosidase, CCL18, osteocalcin, BALP, cathepsin K , TRAP 5, RANKL, OPG, DDK-1, sclerostin, MCP1, IL-2, IL-6, IL-10, SRTH2 and TNF-α
Time frame: 18 months
Measure biomarkers level: molar/mg/h
DMP-1, RANK, OSCAR, cathepsin K, OPG
Time frame: 18 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.